| Literature DB >> 31104842 |
Joseph Mathew Kalappurakkal1, Anupama Ambika Anilkumar2, Chandrima Patra1, Thomas S van Zanten1, Michael P Sheetz3, Satyajit Mayor4.
Abstract
Glycosylphosphatidylinositol-anchored proteins (GPI-APs) are a major class of lipid-anchored plasma membrane proteins. GPI-APs form nanoclusters generated by cortical acto-myosin activity. While our understanding of the physical principles governing this process is emerging, the molecular machinery and functional relevance of GPI-AP nanoclustering are unknown. Here, we first show that a membrane receptor signaling pathway directs nanocluster formation. Arg-Gly-Asp motif-containing ligands bound to the β1-integrin receptor activate src and focal adhesion kinases, resulting in RhoA signaling. This cascade triggers actin-nucleation via specific formins, which, along with myosin activity, drive the nanoclustering of membrane proteins with actin-binding domains. Concurrently, talin-mediated activation of the mechano-transducer vinculin is required for the coupling of the acto-myosin machinery to inner-leaflet lipids, thereby generating GPI-AP nanoclusters. Second, we show that these nanoclusters are functional; disruption of their formation either in GPI-anchor remodeling mutants or in vinculin mutants impairs cell spreading and migration, hallmarks of integrin function.Entities:
Keywords: GPI-anchored proteins; active actin-membrane composite; active rafts; cell signaling; cell spreading; integrin; mechanotransduction; membrane domains; nanoclusters; vinculin
Mesh:
Substances:
Year: 2019 PMID: 31104842 PMCID: PMC6879320 DOI: 10.1016/j.cell.2019.04.037
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582
Figure 1Activation of Fibronectin Binding Integrins Leads to Enhanced Nanoclustering of GPI-APs in Living Cells
(A) Left: experimental schema: GPI-AP-transfected cells were de-adhered and re-plated on glass coverslips with the indicated coatings in serum-free media (SFM). The inset shows GFP or YFP-GPI at the outer leaflet of the PM. Right: in the absence of other contributing factors, the change in anisotropy value of fluorescently tagged GPI-APs reports on the extent of homoFRET due to the proximity of like fluorophores detected using an emission anisotropy TIRF microscope (EA-TIRFM). By convention, anisotropy maps are color coded, with low (or high) anisotropy denoted by blue (or red) pixels that correspond to regions enriched (or depleted) in nanoclusters. Representative intensity and steady-state anisotropy images are shown (B, E, G, and H).
(B–D) GFP-GPI-expressing cells re-plated for 1 h on glass coverslips coated with 1% BSA (red) or 10 μg/mL FN before (blue) or after treatment with 10 mM mβCD for 45 min (green) (B). Graphs show plots of mean anisotropy at various total intensity bins (C) and scatter dot plots with mean anisotropy values (D) of regions of interest (ROIs) obtained from cells plated on BSA-glass (red) or indicated concentrations of FN before (blue) or after treatment with mβCD (green). Note: GPI anisotropy data are represented as scatter dot plots, when fluorescence emission anisotropy is independent of its total intensity.
(E and F) YFP-GPI-expressing CHO cells plated on glass (red) or FN before (blue) (E) or after treatment with mβCD (green) and corresponding anisotropy versus relative intensity (I/Io) plots (F) during photobleaching.
(G–J) CHO cells labeled with the GPI-analog NBD-GPI (exo-GPI: exogenous GPI; G) or C6NBD-sphingomyelin (exo-scSM; H) and re-plated on glass (red, magenta) or on FN (blue, green). Plots in (I) and (J) show mean anisotropy at various total intensity bins. Note that, unlike exo-GPI, the exo-scSM exhibited a concentration-dependent anisotropy with lower anisotropy on glass.
Scale bar, 10 μm in all panels. All the error bars represent SD. Not significant (n.s.) p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Sample size and p values are provided in Table S4.
See also Figure S1.
Figure 2Activation of RGD Binding Integrins Leads to Enhanced Nanoclustering of GPI-APs during the Early Stages of Cell Spreading
(A) Representative intensity and steady-state anisotropy images of GFP-GPI-expressing CHO cells at the indicated times post-settling on FN.
(B) Kymograph shows the time trace of GPI intensity (top) and anisotropy (bottom) of a 3 pixel line (ROI) drawn perpendicular to the cell edge (yellow line in A) exhibiting cell-spreading phases (red lines in top panel); P0–P1 transition (dashed white line in bottom panel) is shown.
(C) Graph shows the change in the whole cell area (red curve; left y axis) and the corresponding normalized GFP-GPI anisotropy change (blue curve; right y axis) between two consecutive frames 15 s apart, plotted as a function of spreading time. The solid white lines in (A) denote the segmented outline of cells used in the graph. Data from 4 cells have been aligned relative to the timing of the peak area change (t = 0 in C). Dots represent the mean for each time bin; shaded region marks the SEM.
(D and E) GFP-GPI-expressing CHO cells grown on glass coverslips and imaged directly (blue) or after incubation (30 min) with indicated concentrations of soluble cRGD (green) either before or after treatment with 10 mM mβCD (red). Scatter dot plot (E) with mean anisotropy values. Note that at high concentrations of cRGD (>100 μM) cell detach due to ligand competition, resulting in higher anisotropy values.
Scale bar, 10 μm in all panels. Error bars represent SD. n.s. p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Sample size and p values are provided in Table S4.
See also Figure S2 and Video S1.
Figure 3Inhibition of SFK-FAK, RhoGTPase, and Formins Leads to Loss of FN-Triggered Nanoclustering of GPI-APs
(A–H) Representative intensity and steady-state anisotropy images and scatter dot plots with mean anisotropy values of ROIs obtained from GFP-GPI-expressing CHO cells re-plated on FN and imaged following pre-treatment with the following:
(A and B) DMSO (blue), SFK inhibitor PP2 (20 μM; green), FAK inhibitor PF-573 228 (10 μM; magenta) or both (black);
(C and D) indicated concentrations of RhoA inhibitor exoenzyme C3 transferase (C3 exo; red) or with the vehicle (H2O;blue) or with mβCD (10 mM, green);
(E and F) formin inhibitor SMIFH2 (10 μM, magenta; top in F) or Arp2/3 inhibitors CK666 (100 μM, green, bottom in F) or respective DMSO vehicle control (blue, orange);
(G and H) formin agonist CN03 (1 μg/mL, green) or RhoA activator IMM01 (10 μM, blue) or with RhoA activator and SMIFH2 (red), all in the presence of 20 μM PP2 and 10 μM PF-573 228.
DMSO pre-treated cells on glass is shown in red in (B) and (F). Scale bar, 10 μm in all panels. All error bars represent SD. n.s. p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Sample size and p values are provided in Table S4.
See also Figure S3.
Figure 4Integrin Activation Triggers Changes in Dynamic Actin Activity and Requires cRGD Ligand Immobilization
(A and B) Schematic of the model transmembrane protein FRTM-Ezrin-AFBD (A) and the mutant FRTM-Ezrin-R579A (FRTM-Ez-AFBD*) (B) that impairs Ezrin-AFBD ability to interact with actin (Gowrishankar et al., 2012).
(C–F) Representative intensity and steady-state anisotropy images and scatter dot plots with mean anisotropy of ROIs obtained from CHO cells stably expressing either FRTM-Ez-AFBD or FRTM-Ez-AFBD* as indicated. The cells were labeled with fluorescent folate, Pteroyl-lysyl-Bodipy(PLB) and plated on FN (blue, green) or glass (red, orange) prior to imaging in the absence (C and D) or after pre-treatment (E and F) with either 20 μM PP2 and 10 μM PF-573228 (red) or 10 μM SMIFH2 (green) or with the vehicle (DMSO; blue).
(G–I) Schematic (G) of the supported lipid bilayer functionalized with cRGD that was prepared either on plain (continuous SLB; top) or on 5-nm-tall and 100-nm-wide chromium patterned (nanopatterned SLB, bottom) glass surfaces. (H and I) GFP-GPI-expressing CHO cells plated on glass (red) or on FN (blue) or treated with 10 mM mβCD on FN (green) or plated on either continuous SLBs with mobile ligand (magenta) or SLBs assembled on chromium nano-patterned surfaces. ROIs were drawn either on the pattern (orange) where the ligand is transiently immobile or from regions outside (brown) where the ligand is mobile.
Scale bar 10μm in all panels. All error bars represent SD. n.s. p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Sample size and p values are provided in Table S4.
See also Figure S4.
Figure 5Talin and Vinculin Are Required for Facilitating GPI-AP Nanoclustering in Mouse Embryonic Fibroblasts
(A–J) Representative intensity and steady-state anisotropy images (A, C, E, G, and I) and scatter dot plot with mean anisotropy values (B, D, F, H, and J) of ROIs obtained from (A and B) vinculin-deficient cells (Vin−/−) transfected with GFP-GPI (blue, orange) or co-transfected with mCherry-vinculin (+Vin-WT; red, green) and plated on FN or subsequently treated with 10 mM mβCD (orange, green).
(C and D) Talin1-deficient cells without (Talin1−/−; blue, red) or with co-transfection with Talin2 shRNA (+Talin2 shR; green, orange) and re-plated onto FN after labeling with Alexa-568-FLAER prior to (blue, green) or post-treatment with 10 mM mβCD (red, orange).
(E and F) Vin−/− cells alone (blue) or transiently transfected with GFP tagged Vin-WT (green), Vin-A50I (orange), or Vin-A50I-CA (brown) and plated onto FN after labeling with Alexa-568-FLAER.
(G and H) Vin−/− cells were transiently transfected with FRTM-Ez-AFBD (FR-EZ; green) or with FR-Ez-AFBD* mutant (FR-EZ*; red), without (open circles) or with Vin-WT (closed circles) and re-plated onto FN after labeling with PLB.
(I and J) Vin−/− cells alone (blue) or transfected with Lact C2-Ez-AFBD YFP (red) were labeled with Alexa-568-FLAER and re-plated on FN and directly labeled or treated with 10 mM mβCD (+mβCD; green). Dotted magenta lines in all images outline the transfected cells expressing the indicated constructs.
Scale bar, 10 μm in all panels. All error bars represent SD. n.s. p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Sample size and p values are provided in Table S4.
See also Figure S5.
Figure 6Vinculin Facilitates GPI-AP Nanoclustering in an Integrin Signaling-Dependent Manner
(A–D) Representative intensity and steady-state anisotropy images and scatter dot plot with mean anisotropy values of ROIs obtained from Alexa-568-FLAER-labeled (A and B) or mRuby2-GPI (C and D)-expressing Vin−/− cells or Vin−/− cells transfected with GFP variants of the indicated vinculin constructs and re-plated on FN prior to imaging. Note: Vin−/−, blue, shows data from Figure 5F, and dotted magenta lines in (A) and (C) outline the transfected cells.
(E) CHO cells transfected with mCherry-vinculin (mCh-Vin-WT) and plated on cRGD functionalized SLBs assembled on nanopatterned surfaces. The dashed line represents the location of the chromium line patterns. Bottom panel: average images of vinculin clusters and correlated GPI-intensity normalized to the maximum, alongside corresponding 3-pixel averaged GPI-anisotropy images obtained from 9 independent vinculin clusters.
(F) Line profiles of normalized mCh-Vin-WT mean intensity (red curve; left-y axis in F), normalized mean GFP-GPI-intensity (green curve; left y axis in F), and mean GFP-GPI-anisotropy (blue curve; right y axis in F) obtained from 10 independent line scans drawn perpendicular to the chromium patterns and passing through the Vin-WT cluster-center. Note, the gray-shaded area (in F) and left side of yellow dotted line (in E, bottom) mark the position of the chromium pattern where the dip in GFP-GPI-intensity is observed.
(G and H) mRuby2-GPI expressed in Vin−/− cells alone (blue) or co-transfected with GFP-Vin-WT (red) or GFP-Vin-CA (green) (G) and plated on mobile cRGD functionalized continuous SLBs and quantified from regions obtained within segmented Vin-CA clusters (orange in H) or for ROIs drawn outside such clusters (magenta in H). Note the diffuse versus clustered distribution of Vin-WT and Vin-CA, respectively, indicating insufficient activation of Vin-WT on continuous SLBs. Scale bar, 10 μm in (A), (C), and (G) and 5 μm (E, top) and 500 nm (E, bottom). All error bars represent SD. n.s. p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Sample size and p values are provided in Table S4.
See also Figure S6.
Figure 7Activity-Generated GPI-AP Nanoclusters Are Necessary for Efficient Cell Spreading on FN
(A and B) Phase-contrast images (A) of Vin−/− cells without or with transient transfection of the indicated GFP-Vin constructs after seeding on FN for the indicated time. Magenta dotted lines outline the transfected cells. Bar graphs (B) show the mean spread area. Inset depicts the cell-spreading profile of Vin−/− cells on FN. Scale bar, 100 μm.
(C and D) Images of WT (blue), PGAP2 and PGAP3 mutant (red), rescued cells (green), or WT cells pre-treated with 10 mM mβCD after seeding on FN for the indicated time. The corresponding mean cell-spread area profile is shown in (D). Scale bar, 100 μm and 25 μm (inset).
(E) Plot of mean cell-spread-area change, between two consecutive frames of 15 s, as a function of spreading time on FN for the indicated cell lines. Shaded error bar represents SEM.
(F) Representative phalloidin-actin-stained images and scatter dot plot with the mean whole cell spread area of the indicated cell lines plated on anti-CD59 functionalized glass surfaces. Scale bars, 10 μm.
(G) Model for the integrin triggered generation of functional GPI-APs nanoclusters. Refer to Discussion for details.
All error bars represent SD except in (E). n.s. p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Sample size and p values are provided in Table S4.
See also Figure S7 and Videos S2 and S3.
Key Resources Table
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Antibodies | ||
| Diap1(mDia1) Antibody | Cell Signaling Technology | Cat# 5486; RRID: AB_10828440 |
| FHOD1 Antibody | ECM Biosciences | Cat# FM3521; RRID: AB_2104508 |
| Integrin β1 Antibody,non-function perturbing, K20 | Santa Cruz | Cat# sc-18887; RRID: AB_627006 |
| Integrin β1 Antibody,blocking, 4B4 | Beckman Coulter | Cat# 6603113; RRID: AB_10638675 |
| Integrin β1 Antibody, activated, clone HUTS-4 | Merck | Cat# MAB2079Z; RRID: AB_2233964 |
| Transferin Antibody,OKT9 | Purified from hybridoma cells procured from National Centre for Cell Science,Pune,India | NA |
| FR Antibody, MOv 19 | Dr Silvana Canevari (Fondazione IRCCS Istituto Nazionale dei tumori di Milano,Italy) | NA |
| CD59 Antibody, MEM-43 | Abcam | Cat# ab9182; RRID: AB_307053 |
| Talin Antibody, Clone 8D4 | Sigma Aldrich | Cat# SAB4200694 |
| Vinculin Antibody, Clone SPM227 | Abcam | Cat# ab18058; RRID: AB_444215 |
| Paxillin Antibody | BD Transduction Labs | Cat# 610051; RRID: AB_397463 |
| AffiniPure Donkey Anti-Mouse IgG (H+L) | Jackson ImmunoResearch Laboratories, Inc. | Cat# 715-005-150; RRID: AB_2340758 |
| β-actin Antibody | Sigma Aldrich | Cat# A5060; RRID: AB_476738 |
| Peroxidase AffiniPure Donkey Anti-Rabbit IgG (H+L) | Jackson ImmunoResearch Laboratories, Inc. | Cat# 711-035-152; RRID: AB_10015282 |
| Peroxidase-AffiniPure Goat Anti-Mouse IgG (H+L) | Jackson ImmunoResearch Laboratories, Inc. | Cat# 115-035-003; RRID: AB_10015289 |
| CaptureSelect Biotin Anti-IgG-Fc (Multi-species) Conjugate | Thermo Scientific | Cat# 7102852100 |
| Chemicals, Peptides, and Recombinant Proteins | ||
| Human Plasma Fibronectin Purified Protein | Merck (Sigma Aldrich) | Cat# FC010 |
| H-Gly-Pen-Gly-Arg-Gly-Asp-Ser-Pro-Cys-Ala-OH trifluoroacetate salt (Disulfide bond between Pen2 and Cys9) | Bachem | Cat# H-3964 |
| SFK Inhibitor; PP2 | Calbiochem (Merck) | Cat# 529573 |
| FAK Inhibitor; PF 573228 | Sigma Aldrich | Cat# PZ0117 |
| C3 exoenzyme; Rho Inhibitor I | Cytoskeleton, Inc. | Cat# CT04 |
| Rho Activator II | Cytoskeleton, Inc. | Cat# CN03 |
| Formin Inhibitor; SMIFH2 | Sigma Aldrich | Cat# S4826 |
| Arp2/3 Inhibitor; CK666 | Sigma Aldrich | Cat# SML0006 |
| ROCK Inhibitor; Y-27632 dihydrochloride | Sigma Aldrich | Cat# Y0503 |
| MLCK Inhibitor; ML-7 | Sigma Aldrich | Cat# I2764 |
| 18:1 (Δ9-Cis) PC (DOPC) 1,2-dioleoyl-sn-glycero-3-phosphocholine | Avanti Polar Lipids, Inc. | Cat# 850375 |
| 16:0 Biotinyl Cap PE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(cap biotinyl) (sodium salt) | Avanti Polar Lipids, Inc. | Cat# 870277 |
| NeutrAvidin Protein, DyLight 650 | Invitrogen (Thermo Fisher Scientific) | Cat# 84607 |
| Avidin, NeutrAvidin Biotin-binding Protein | Invitrogen (Thermo Fisher Scientific) | Cat# A2666 |
| Cyclo[Arg-Gly-Asp-D-Phe-Lys(Biotin-PEG-PEG)] | Peptides International | Cat# PCI-3697-PI |
| Laminin from Engelbreth-Holm-Swarm murine sarcoma basement membrane | Sigma Aldrich | Cat# L2020 |
| Collagen I Rat Protein, Tail | GIBCO (Thermo Fisher Scientific) | Cat# A1048301 |
| Poly-L-lysine solution, 0.01% | Sigma Aldrich | Cat# P4707 |
| Vitronectin from Human Plasma | Sigma Aldrich | Cat# V9881 |
| Methyl-β-cyclodextrin | Sigma Aldrich | Cat# C4555 |
| FuGENE® 6 Transfection Reagent, For plasmid DNA transfections | Promega | Cat# E2692 |
| HiPerFect Transfection Reagent, For siRNA transfections | QIAGEN | Cat# 301704 |
| Diaphanous (mDia)-related Formin Agonist, IMM01 | Merck Millipore | Cat# 509583 |
| 6-Dodecanoyl-N,N-dimethyl-2-naphthylamine | Sigma Aldrich | Cat# 40227 |
| Filipin III from | Sigma Aldrich | Cat# F4767 |
| Alexa Fluor 488 phalloidin | Invitrogen (Thermo Fisher Scientific) | Cat# A12379 |
| Alexa Fluor 568 phalloidin | Invitrogen (Thermo Fisher Scientific) | Cat# A12380 |
| PLL(20)-g[3.5]-PEG(2)/PEG(3.4)biotin 50% | SuSoS | Cat# PLL(20)-g[3.5]-PEG(2)/PEG(3.4) biotin 50% |
| Proaerolysin | Protein Technology Core (C-CAMP,Bangalore,India) | N/A |
| Alexa 488- conjugated FLAER | Protox Biotech | Cat# FL1S |
| Hellmanex III | Hellma Analystics (Sigma Aldrich) | Cat# Z805939 |
| Experimental Models: Cell Lines | ||
| GG8;CHO-K1 cells (TRVb-1), devoid of transferrin receptor (TfR) were stably transfected with human TfR and EGFP-GPI | Satyajit Mayor ( | N/A |
| U2OS; Human Osetosarcoma cells | Clare Waterman (NHLBI,NIH,USA) ( | N/A |
| U2OS GG; U2OS cells stably transfected with GFP-GPI | This paper | N/A |
| Vin−/− MEFs;Mouse embryonic fibroblasts deficient in vinculin | Daniel Rösel (Charles University in Prague, Czech Republic) ( | N/A |
| GD3S-C37;3B2A cells (CHO cells stably expressing CD59 and DAF) stably expressing GD3 synthase | Taroh Kinoshita (Osaka University, Japan)( | N/A |
| C84 DM2&3-C2;PGAP2/3 double mutant cell line stably expressing CD59 and DAF | Taroh Kinoshita (Osaka University, Japan)( | N/A |
| C84 DM2&3-C2 + pMSCV-rPGAP2-zeo-hPGAP3;PGAP2/3 double mutant cells expressing PGAP2 and PGAP3 | Taroh Kinoshita (Osaka University, Japan) ( | N/A |
| Talin 1 deficient MEFs; Mouse embryonic fibroblasts deficient in talin 1 | Mike Sheetz (Mechanobiology Institute, Singapore) ( | N/A |
| CHOB2-α5-GFP;CHOB2 (that lack endogenous a5integrin) cells stably expressing GFP-a5 integrin | Alan F Horwitz (University of Virginia,USA) ( | N/A |
| FAK −/− MEFs; Mouse embryonic fibroblasts that have null mutations in FAK and p53 gene derived from E 8.0 embryo | ATCC ( | Cat# CRL-2644; RRID: CVCL_8954 |
| FAK +/+ MEFs;Mouse embryonic fibroblasts in which there is mutation in only the p53 gene and used as a control for the FAK−/− line | ATCC ( | Cat# CRL-2645; RRID: CVCL_8955 |
| MYG1;m-YFP GPI expressing CHO cells | Satyajit Mayor (Suvrajit Saha PhD Thesis) | N/A |
| Oligonucleotides | ||
| Primers used to generate the GFP-Vinculin Ld CA | See | N/A |
| Primers used to generate the GFP-Vinculin Ld construct | See | N/A |
| Primers used to generate the Lact C2 AAA-Ezrin AFBD-YFP construct | See | N/A |
| ON-TARGETplus Non-targeting siRNA | Dharmacon | Cat# D-001810-01-05 |
| siGENOME Human FHOD1 siRNA SMART Pool | Dharmacon | Cat# M-013709-01-0005 |
| siGENOME Human DIAPH1 siRNA SMART Pool | Dharmacon | Cat# M-010347-02-0005 |
| Primers used to generate the mRuby2-GPI construct | See | N/A |
| Recombinant DNA | ||
| Talin 2 shRNA | Mike Sheetz (Mechanobiology Institute, Singapore) ( | N/A |
| GFP-Vinculin WT;Full length | Clare Waterman (NHLBI,NIH,USA) ( | N/A |
| mCherry-Vinculin WT;Full length | Clare Waterman (NHLBI,NIH,USA) ( | N/A |
| GFP-Vinculin CA;constitutively active | Clare Waterman (NHLBI,NIH,USA) ( | N/A |
| GFP-Vinculin A50I;Talin non-binding | Clare Waterman (NHLBI,NIH,USA) ( | N/A |
| GFP-Vinculin A50I CA;Talin non-binding constitutively active | Clare Waterman (NHLBI,NIH,USA) ( | N/A |
| GFP-Vinculin Ld; Lipid non-binding | This Paper | N/A |
| GFP-Vinculin Ld CA; Lipid non-binding constiutively active | This Paper | N/A |
| GFP-Vinculin AB1; Actin non-binding | Clare Waterman (NHLBI,NIH,USA) ( | N/A |
| GFP-Vinculin AB1 CA; Actin non-binding constitutively active | Clare Waterman (NHLBI,NIH,USA) ( | N/A |
| GFP-Vinculin head; head domain of vinculin | Clare Waterman (NHLBI,NIH,USA) ( | N/A |
| Lact C2 Ezrin AFBD-YFP | Protein Technology Core (C-CAMP,Bangalore,India) ( | N/A |
| Lact C2-AAA Ezrin AFBD-YFP | This Paper | N/A |
| GFP-Vinculin AB2; Actin non-binding constitutively active | Clare Waterman (NHLBI,NIH,USA) ( | N/A |
| mRFP-tH | John F.Hancock (University of Queensland,Australia) ( | N/A |
| mRuby2-GPI | This Paper | N/A |
| pcDNA3-mRuby2 | Michael Lin (Stanford University, USA) ( | Addgene plasmid # 40260; |
| Software and Algorithms | ||
| MATLAB, Image processing toolbox | Mathworks Inc. | |
| Fiji Image analysis software | ||
| GraphPad Prism 7 software | GraphPad | |
| 5′-GCT GCA GCC ATG AGT GGG G-3′ | |
| 5′-CAG GTC CTC CTC GCT TAT TAG TTT TTG-3′ |
| 5′-AAC TAA TAA GCG AGG AGG ACC TGA TGG TGT CTA AGG GCG AAG-3′ | |
| 5′-GCC CCA CTC ATG GCT GCA GCC TTG TAC AGC TCG TCC ATC-3′ |
| 5′- | |
| 5′-GGC ACA CTG AAT AAG TGC CCG CTT-3′ |
| 5′ -TGC ACA GCT GCG GCG ATT | |
| 5′ -TAC CTG TAA GAG ATT GGT | |
| 5′ -ACT CTG CGC TGG GTC | |
| 5′ -GTA CCA GGG AGT CTT | |
| 5′ -CTG CGC TGG GTC CAA | |
| 5′ -CTG GTA CCA GGG AGT CTG TTG GAC CCA GCG CAG-3′ |
| 5′ | |
| 5′ -GGC ACA CTG AAT AAG TGC CCG CTT-3′ | |
| 5′ -ACT CTG CGC TGG GTC | |
| 5′ -GTA CCA GGG AGT CTT | |
| 5′ -CTG CGC TGG GTC CAA | |
| 5′ -CTG GTA CCA GGG AGT CTG TTG GAC CCA GCG CAG-3′ |
| 5′-(GGG) | |
| : 5′-CAGGTTTTGTAGTAGCTGGAGGCTGTGATCTGCTTGTTGGGGATG-3′ |